Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

Michael B. Harbut, Catherine Vilchèze, Xiaozhou Luo, Mary E. Hensler, Hui Guo, Baiyuan Yang, Arnab K. Chatterjee, Victor Nizet, William R. Jacobs, Peter G. Schultz, Feng Wang

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Infections caused by antibiotic-resistant bacteria are a rising public health threat and make the identification of new antibiotics a priority. From a cell-based screen for bactericidal compounds against Mycobacterium tuberculosis under nutrient-deprivation conditions we identified auranofin, an orally bioavailable FDA-approved antirheumatic drug, as having potent bactericidal activities against both replicating and nonreplicating M. tuberculosis. We also found that auranofin is active against other Gram-positive bacteria, including Bacillus subtilis and Enterococcus faecalis, and drug-sensitive and drug-resistant strains of Enterococcus faecium and Staphylococcus aureus. Our biochemical studies showed that auranofin inhibits the bacterial thioredoxin reductase, a protein essential in many Gram-positive bacteria for maintaining the thiol-redox balance and protecting against reactive oxidative species. Auranofin decreases the reducing capacity of target bacteria, thereby sensitizing them to oxidative stress. Finally, auranofin was efficacious in a murine model of methicillin-resistant S. aureus infection. These results suggest that the thioredoxin-mediated redox cascade of Gram-positive pathogens is a valid target for the development of antibacterial drugs, and that the existing clinical agent auranofin may be repurposed to aid in the treatment of several important antibiotic-resistant pathogens.

Original languageEnglish (US)
Pages (from-to)4453-4458
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number14
DOIs
StatePublished - Apr 7 2015

Fingerprint

Auranofin
Sulfhydryl Compounds
Oxidation-Reduction
Homeostasis
Gram-Positive Bacteria
Anti-Bacterial Agents
Mycobacterium tuberculosis
Pharmaceutical Preparations
Thioredoxin-Disulfide Reductase
Bacteria
Enterococcus faecium
Thioredoxins
Antirheumatic Agents
Enterococcus faecalis
Methicillin-Resistant Staphylococcus aureus
Infection
Bacillus subtilis
Staphylococcus aureus
Oxidative Stress
Public Health

Keywords

  • Auranofin
  • Gram-positive
  • MRSA
  • Tuberculosis

ASJC Scopus subject areas

  • General

Cite this

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. / Harbut, Michael B.; Vilchèze, Catherine; Luo, Xiaozhou; Hensler, Mary E.; Guo, Hui; Yang, Baiyuan; Chatterjee, Arnab K.; Nizet, Victor; Jacobs, William R.; Schultz, Peter G.; Wang, Feng.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 14, 07.04.2015, p. 4453-4458.

Research output: Contribution to journalArticle

Harbut, Michael B. ; Vilchèze, Catherine ; Luo, Xiaozhou ; Hensler, Mary E. ; Guo, Hui ; Yang, Baiyuan ; Chatterjee, Arnab K. ; Nizet, Victor ; Jacobs, William R. ; Schultz, Peter G. ; Wang, Feng. / Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 14. pp. 4453-4458.
@article{e638966c22fe40a982f82a8c52e88a31,
title = "Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis",
abstract = "Infections caused by antibiotic-resistant bacteria are a rising public health threat and make the identification of new antibiotics a priority. From a cell-based screen for bactericidal compounds against Mycobacterium tuberculosis under nutrient-deprivation conditions we identified auranofin, an orally bioavailable FDA-approved antirheumatic drug, as having potent bactericidal activities against both replicating and nonreplicating M. tuberculosis. We also found that auranofin is active against other Gram-positive bacteria, including Bacillus subtilis and Enterococcus faecalis, and drug-sensitive and drug-resistant strains of Enterococcus faecium and Staphylococcus aureus. Our biochemical studies showed that auranofin inhibits the bacterial thioredoxin reductase, a protein essential in many Gram-positive bacteria for maintaining the thiol-redox balance and protecting against reactive oxidative species. Auranofin decreases the reducing capacity of target bacteria, thereby sensitizing them to oxidative stress. Finally, auranofin was efficacious in a murine model of methicillin-resistant S. aureus infection. These results suggest that the thioredoxin-mediated redox cascade of Gram-positive pathogens is a valid target for the development of antibacterial drugs, and that the existing clinical agent auranofin may be repurposed to aid in the treatment of several important antibiotic-resistant pathogens.",
keywords = "Auranofin, Gram-positive, MRSA, Tuberculosis",
author = "Harbut, {Michael B.} and Catherine Vilch{\`e}ze and Xiaozhou Luo and Hensler, {Mary E.} and Hui Guo and Baiyuan Yang and Chatterjee, {Arnab K.} and Victor Nizet and Jacobs, {William R.} and Schultz, {Peter G.} and Feng Wang",
year = "2015",
month = "4",
day = "7",
doi = "10.1073/pnas.1504022112",
language = "English (US)",
volume = "112",
pages = "4453--4458",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "14",

}

TY - JOUR

T1 - Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis

AU - Harbut, Michael B.

AU - Vilchèze, Catherine

AU - Luo, Xiaozhou

AU - Hensler, Mary E.

AU - Guo, Hui

AU - Yang, Baiyuan

AU - Chatterjee, Arnab K.

AU - Nizet, Victor

AU - Jacobs, William R.

AU - Schultz, Peter G.

AU - Wang, Feng

PY - 2015/4/7

Y1 - 2015/4/7

N2 - Infections caused by antibiotic-resistant bacteria are a rising public health threat and make the identification of new antibiotics a priority. From a cell-based screen for bactericidal compounds against Mycobacterium tuberculosis under nutrient-deprivation conditions we identified auranofin, an orally bioavailable FDA-approved antirheumatic drug, as having potent bactericidal activities against both replicating and nonreplicating M. tuberculosis. We also found that auranofin is active against other Gram-positive bacteria, including Bacillus subtilis and Enterococcus faecalis, and drug-sensitive and drug-resistant strains of Enterococcus faecium and Staphylococcus aureus. Our biochemical studies showed that auranofin inhibits the bacterial thioredoxin reductase, a protein essential in many Gram-positive bacteria for maintaining the thiol-redox balance and protecting against reactive oxidative species. Auranofin decreases the reducing capacity of target bacteria, thereby sensitizing them to oxidative stress. Finally, auranofin was efficacious in a murine model of methicillin-resistant S. aureus infection. These results suggest that the thioredoxin-mediated redox cascade of Gram-positive pathogens is a valid target for the development of antibacterial drugs, and that the existing clinical agent auranofin may be repurposed to aid in the treatment of several important antibiotic-resistant pathogens.

AB - Infections caused by antibiotic-resistant bacteria are a rising public health threat and make the identification of new antibiotics a priority. From a cell-based screen for bactericidal compounds against Mycobacterium tuberculosis under nutrient-deprivation conditions we identified auranofin, an orally bioavailable FDA-approved antirheumatic drug, as having potent bactericidal activities against both replicating and nonreplicating M. tuberculosis. We also found that auranofin is active against other Gram-positive bacteria, including Bacillus subtilis and Enterococcus faecalis, and drug-sensitive and drug-resistant strains of Enterococcus faecium and Staphylococcus aureus. Our biochemical studies showed that auranofin inhibits the bacterial thioredoxin reductase, a protein essential in many Gram-positive bacteria for maintaining the thiol-redox balance and protecting against reactive oxidative species. Auranofin decreases the reducing capacity of target bacteria, thereby sensitizing them to oxidative stress. Finally, auranofin was efficacious in a murine model of methicillin-resistant S. aureus infection. These results suggest that the thioredoxin-mediated redox cascade of Gram-positive pathogens is a valid target for the development of antibacterial drugs, and that the existing clinical agent auranofin may be repurposed to aid in the treatment of several important antibiotic-resistant pathogens.

KW - Auranofin

KW - Gram-positive

KW - MRSA

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84928920149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928920149&partnerID=8YFLogxK

U2 - 10.1073/pnas.1504022112

DO - 10.1073/pnas.1504022112

M3 - Article

C2 - 25831516

AN - SCOPUS:84928920149

VL - 112

SP - 4453

EP - 4458

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 14

ER -